siRNA- and miRNA-based therapeutics for liver fibrosis
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Liver fibrosis is a wound-healing process induced by chronic liver injuries, such as nonalcoholic steatohepatitis, hepatitis, alcohol abuse, and metal poisoning. The accumulation of excessive extracellular matrix (ECM) in the liver is a key characteristic of liver fibrosis. Activated hepatic stellate cells (HSCs) are the major producers of ECM and therefore play irreplaceably important roles during the progression of liver fibrosis. Liver fibrogenesis is highly correlated with the activation of HSCs, which is regulated by numerous profibrotic cytokines. Using RNA interference (RNAi) to downregulate these cytokines in activated HSCs is a promising strategy to reverse liver fibrosis. Meanwhile, microRNAs (miRNAs) have also been exploited for the treatment of liver fibrosis. This review focuses on the current siRNA- and miRNA-based liver fibrosis treatment strategies by targeting activated HSCs in the liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 1×
“For example, antagomirs are a class of chemically modified oligonucleotides that specifically and efficiently block the functions of upregulated miRNA.(118,119) Antagomirs are, therefore, used to treat diseases caused by upregulated miRNAs.”
BackgroundHayden, M. S., & Ghosh, S. (2004) · Genes & Development · doi:10.1101/gad.1228704 · Cited by 3,842
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis
Mokdad, A. A., Lopez, A. D., Shahraz, S., Lozano, R., Mokdad, A. H., Stanaway, J., Murray, C. J., & Naghavi, M. (2014) · BMC Medicine · doi:10.1186/s12916-014-0145-y · Cited by 1,129 · cited 1×
“Liver fibrosis and cirrhosis were found at high risk in patients who have chronic hepatitis B (CHB) or C (CHC).(137,138) In an early 250 patients enrolled study, serum miR-122 were determined at a lower level in patients with hepatic decompensation compared to compensated liver disease group, indicating that the serum…”
BackgroundHistory, Heterogeneity, Developmental Biology, and Functions of Quiescent Hepatic Stellate Cells
Geerts, A. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-17550 · Cited by 740
TGF‐β signalling and liver disease
Fabregat, I., Moreno‐Càceres, J., Sánchez, A., Dooley, S., Dewidar, B., Giannelli, G., ten Dijke, P., & the IT‐LIVER Consortium (2016) · The FEBS Journal · doi:10.1111/febs.13665 · Cited by 600
Lipid nanoparticles enabling gene therapies: from concepts to clinical utility
Kulkarni, J. A., Cullis, P. R., & van der Meel, R. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0721 · Cited by 592 · cited 1×
“A number of siRNA-based therapies are now in clinical trials, and one of them is the lipid nanoparticle containing HSP47 siRNA for the treatment of liver fibrosis (NCT02227459).(23) During the progression of liver fibrosis, numerous membrane receptor signaling pathways, nuclear receptor signaling pathways, and transcr…”
BackgroundSanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31785-9 · Cited by 550
Murphy, F. R., Issa, R., Zhou, X., Ratnarajah, S., Arthur, M. J. P., Benyon, C., Iredale, J. P., & Nagase, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111490200 · Cited by 432 · cited 16×
“The results showed that NLRC5 was overexpressed during liver fibrosis and increased the expression of a-SMA and Col1a in ARTICLE IN PRESS Translational Research 8 Zhao et al 2019 factor receptor 1 pathway regulates the activation of lipopolysaccharide‑induced HSCs. Fibroblast growth factor receptor 1-targeted siRNA de…”
BackgroundInfluential
Cited by
Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease
Wu, X., Fan, X., Miyata, T., Kim, A., Cajigas-Du Ross, C. K., Ray, S., Huang, E., Taiwo, M., Arya, R., Wu, J., et al. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-030435 · Cited by 289
Zhou, Q., Rong, C., Gu, T., Li, H., Wu, L., Zhuansun, X., Zhao, X., Xiao, Z., Kuang, Y., Xu, S., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03030-8 · Cited by 43
Sinusoidal communication in chronic liver disease
Gibert-Ramos, A., Andrés-Rozas, M., Pastó, R., Alfaro-Retamero, P., Guixé-Muntet, S., & Gracia-Sancho, J. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0734 · Cited by 20
“For this reason, their modulation is being considered as promising therapy(148).”
Background
Metadata
- Authors
- Zhao, Z., Lin, C.-Y., & Cheng, K.
- Venue
- Translational Research
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 214
- Pages
- 17-29
- ISSN
- 1878-1810 (ISSN-L)
- 1931-5244
- OpenAlex
- W2969046382
- Cited by
- 106
- References
- 15
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: siRNA- and miRNA-based therapeutics for liver fibrosis. https://app.cochat.ai/papers/10.1016/j.trsl.2019.07.007
- The paper
- Zhao, Z., Lin, C.-Y., & Cheng, K. (2019). siRNA- and miRNA-based therapeutics for liver fibrosis. Translational Research. https://doi.org/10.1016/j.trsl.2019.07.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.